CYPH — Cypherpunk Technologies Share News
0.000.00%
Last trade - 00:00- $321.14m
- $313.51m
U.S. RESEARCH ROUNDUP-Abbvie, Eli Lilly, Vroom
Leap Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Leap Therapeutics Reports Q3 2022 Financial Results
Leap Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Leap Therapeutics Announces First Patient Enrolled In Defiance Study Of Dkn-01 For The Treatment Of Colorectal Cancer Patients
Brief: Leap Therapeutics Enrolls First Patient In Part C Of Phase 2 Distinguish Study Of Dkn-01 In Combination With Tislelizumab For The Treatment Of Gastric Or Gastroesophageal Junction Cancer
U.S. RESEARCH ROUNDUP- PLx pharma, Vroom, Walmart
Leap Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Leap Therapeutics' Board Of Directors Member Dr. Monica Bertagnolli appointed as the Director of The National Cancer Institute
Brief: Leap Therapeutics reports Q2 results
Leap Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Leap Therapeutics Announces Initiation Of New Dkn-01 Clinical Trials In Gastric Cancer, Colorectal Cancer And Endometrial Cancer
Leap Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Leap Therapeutics Reports First Quarter 2022 Financial Results
Leap Therapeutics Inc expected to post a loss of 10 cents a share - Earnings Preview
Leap Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Leap Therapeutics Reports Qtrly Loss Per Share Of $0.10
Leap Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Leica Biosystems, Leap Therapeutics Partner On Companion Diagnostic To Advance Care For Cancer Patients